Considerations in building a pipeline of mAb biosimilars for emerging markets
Bringing a drug to market is a complicated process. Bringing a drug to an emerging market requirs a different set of considerations.
Download this presentation by Roman Ivanov to find out more:
- Characteristics of emerging markets
- Regulatory environment for biosimilars
- BCD-020 – rituximab biosimilar Non-clinical studies
- BCD-020 – rituximab biosimilar Clinical studies
- Challenges
- Interchangeability of biologics
- Incentives for local manufacturing
- Success factors for emerging markets
Thank you for your interest. To receive your copy of the PDF, please fill in the form to your right.
Thanks,
World Biosimilar Congress Team